Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults
- 5 August 2008
- journal article
- research article
- Published by Elsevier BV in Vaccine
- Vol. 26 (33), 4160-4167
- https://doi.org/10.1016/j.vaccine.2008.05.077
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trialThe Lancet, 2007
- Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trialThe Lancet, 2006
- Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trialThe Lancet, 2006
- Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) VaccineThe New England Journal of Medicine, 2006
- Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality systemVaccine, 2005
- Cross‐Reactivity to Highly Pathogenic Avian Influenza H5N1 Viruses after Vaccination with Nonadjuvanted and MF59‐Adjuvanted Influenza A/Duck/Singapore/97 (H5N3) Vaccine: A Potential Priming StrategyThe Journal of Infectious Diseases, 2005
- Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccineVirus Research, 2004
- Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutininJournal of Medical Virology, 2003
- Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenzaThe Lancet, 2001
- Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humansVaccine, 2001